Objective: In the present study we investigated the importance of protease-activated receptor (PAR)-2 and its ligand mast cell tryptase in the development of PH.
P ulmonary hypertension (PH) is characterized by a persistent increase in pulmonary arterial pressure, which can ultimately lead to right ventricular failure and death. Factors that contribute to the increased vascular resistance in PH include vasoconstriction, vascular remodeling, and thrombosis. 1 Pulmonary vasoconstriction can result from the imbalance of vasoactive mediators such as nitric oxide, endothelin-1, prostacyclin, and serotonin. Another potent stimulator of arterial contraction is alveolar hypoxia. Low oxygen levels down-regulate voltage-gated potassium channels, leading to depolarization of smooth muscle cells (SMC), subsequent Ca 2ϩ influx, and vasoconstriction. [2] [3] [4] Prolonged contraction stimulates the proliferation and migration of SMC and fibroblasts leading to medial or adventitial thickening of the pulmonary arteries. 1 Remodeling can also be triggered by a dysfunction of endothelial cells, thereby altering vascular homeostasis by changing cytokine/growth factor levels and procoagulant potential. 1 Vascular damage and endothelial dysfunction can alter the composition of the extracellular matrix by the induction of matrix metalloproteinases (MMPs), resulting in SMC migration and proliferation. 5 Accumulating evidence suggests that inflammatory cells may play an active role in the development of PH. 6, 7 The number of mast cells is increased in patients with primary and secondary PH. 8 Mast cells are known to participate in various types of tissue remodeling through release of biologically active mediators, including the serine protease tryptase. Expression of tryptase is restricted almost exclusively to mast cells, where it is found within the secretory granules in a complex with heparin. 9, 10 Once released, tryptase potentiates histamine-mediated contractility of airway smooth muscle, degrades vasoactive intestinal peptides, and stimulates proliferation of fibroblasts, epithelial cells, and SMC. [11] [12] [13] The cellular effects of tryptase are mediated via the cleavage of the protease-activated receptor (PAR)-2. Protease-activated receptors (PARs) are a subfamily of G-protein-coupled receptors, which play important roles in coagulation, inflammation, and vascular homeostasis. 14 -16 Activation of these receptors requires the cleavage of the extracellular N-terminal domain, generating a tethered ligand that binds to the extracellular loop II of the receptor to initiate signaling. 10 PAR-2 exhibits wide-spread tissue distribution including brain, heart, intestine, kidney, lung, and pancreas. Activation of PAR-2 in human airway SMC can mobilize intracellular calcium stores, consequently leading to cell contraction. 17 In the respiratory epithelium, PAR-2 stimulates the release of inflammatory mediators such as IL-6, IL-8, PGE2, and MMP-9, suggesting an important role of PAR-2 in inflammation and tissue remodeling. 18, 19 In addition, elevated expression of PAR-2 has been demonstrated in vascular lesions following balloon angioplasty in rats and baboons and in human advanced atherosclerotic plaques. 20 Taking together, these suggest that PAR-2 may have an important role in various pathological conditions. However, its role in the pulmonary vasculature specifically with respect to PH has not yet been defined. Therefore, we have investigated the contribution of the tryptase-PAR-2 axis to the pathogenesis of PH both in animals and in humans and found that PAR-2 plays a novel role in pulmonary vascular remodeling.
Methods
A detailed description of routine methodologies is provided in the Online Supplement. Only specialized materials are described in this section.
Animal Experiments
All animal experiments were performed in accordance with institutional and national guidelines for the care and use of experimental animals. For hypoxic exposures, male wild-type and PAR-2 Ϫ/Ϫ mice were placed in a ventilated chamber system with a FiO 2 of 0.10. To induce PH in rats, we injected male Sprague-Dawley rats with monocrotaline as described previously. 21 After 21 days, rats challenged with monocrotaline and mice exposed to hypoxia were randomized and treated orally once daily with 100 mg/kgbw STI571 (Imatinib/Glivec, Norvatis) for 14 days. The control animals received vehicle. Therapeutic effects of PAR-2 inhibition were assessed in mice exposed to hypoxia for 35 days. Briefly, animals were kept in hypoxic conditions to develop PH. After 21 days, animals were randomized to receive daily intraperitoneal injections of either PAR-2 antagonist FSLLRY-amide (4 mg/kgbw, Bachem, Bubendorf, Switzerland) or placebo.
Human Material
The investigations have been conducted according to the Declaration of Helsinki principles and were approved by the local institutional review board and ethics committee. Informed consent was obtained from either the patients or their next of kin. Lung tissue was obtained from 7 idiopathic pulmonary arterial hypertension (IPAH) patients (Online Table I ) who underwent lung transplantation at the Department of Cardiothoracic Surgery, Medical University of Vienna, Austria (Director W. Klepetko). Nonutilized donor lungs served as a control (nϭ7). Citrated plasma samples were collected from 21 IPAH patients (Online Table II ) and 20 age-matched healthy subjects.
PASMC
Pulmonary artery smooth muscle cells (PASMC) used for all the experiments applied in the manuscript were isolated from nonutilized human donor lungs harvested for lung transplantation that were not implanted because of lack of compatibility. PASMC were isolated from human resistance pulmonary arteries (from third intrapulmonary branch, diameter Ͻ1 mm).
Statistical Analysis
Data are presented as meanϮstandard error of the mean (SEM) for all studies. Statistical differences between groups were calculated using nonparametric tests; for multigroup comparison Kruskal-Wallis test in combination with Dunn's posthoc test, for pairedsamples Wilcoxon matched-pairs test and for unpaired-samples Mann-Whitney test. For densitometric analysis of cell culture experiments t test was applied. PϽ0.05 were considered significant. All experiments were designed with matched control conditions to enable statistical comparison.
Results

PAR-2 Levels in Lungs From IPAH Patients and Animal Models of PH
To assess the importance of PAR-2 in PH, we have analyzed PAR-2 localization and expression in experimental and human PH. In mouse lung parenchyma the strongest PAR-2 immunoreactivity was observed in vascular and bronchial structures ( Figure 1A and Online Figure IA ). Staining of adjacent sections for ␣-smooth muscle actin (␣-SMA) revealed predominant PAR-2 expression in SMC. Direct comparison of PAR-2 staining between lung sections from hypoxic and normoxic mice demonstrated stronger PAR-2 immunoreactivity in lungs from hypoxia-exposed animals ( Figure 1A ). Furthermore, double immunofluorescence staining confirmed strong PAR-2 signal in SMC of pulmonary vessels of mice exposed to hypoxia (Online Figure IB) . To show that PAR-2 expression is elevated in hypoxia-induced PH, we analyzed PAR-2 levels in mouse lung homogenates by real-time polymerase chain reaction (PCR) and Western blotting. PAR-2 mRNA and protein were strongly induced in mice exposed to hypoxia for 1 day (Online Figure IC through IE). After 21 days exposure to hypoxia, PAR-2 levels declined but still remained elevated in comparison with controls (Online Figure IC through IE). No change in PAR-2 expression was observed in the carotid artery and aorta isolated from mice maintained under hypoxic conditions in comparison with normoxia (Online Figure IF and IG). Moreover, no change in cardiac PAR-2 expression was detected in hypoxia-exposed mice versus normoxia (Online Figure IH) . In the rat monocrotaline (MCT) model, PAR-2 expression primarily localized to SMC of the intrapulmonary vessels and the bronchial tree ( Figure 1B and Online Figure IIA ). Presence of PAR-2 in SMC of pulmonary vessels of MCTinjected rats was also demonstrated by double immunofluorescence staining (Online Figure IIB) . Higher expression of PAR-2 was detected in the lung homogenates of MCT-treated rats in comparison with control animals (Online Figure IIC through IE). Moreover, PAR-2 levels were strongly elevated in PASMC isolated from precapillary vessels of MCTchallenged rats in comparison with PASMC isolated from sham-treated animals (Online Figure IIF and IIG). In human lung samples, immunochemical staining predominantly localized PAR-2 to SMC within the pulmonary vasculature (Figure 1C ) and bronchial tree (not shown). Interestingly, the strongest immunoreactivity for PAR-2 was observed in remodeled vessels of IPAH patients ( Figure 1C ). Double immunofluorescence staining of lung tissue sections from IPAH patients confirmed strong PAR-2 signal in remodeled vessels (Online Figure IIIA ). Furthermore, real-time PCR and Western blotting demonstrated significantly higher PAR-2 levels in IPAH patient lung samples than in donors (Online Figure IIIB through IIID).
In contrast to PAR-2, a consistent differential regulation in human and experimental PH was not observed for any other member of the PAR family (Online Figure IVA 
Hypoxia-Dependent Expression of PAR-2 in PASMC
We next performed dual immunofluorescence staining against ␣-SMA and PAR-2 in isolated PASMC, which confirmed expression of PAR-2 by this cell population (Online Figure VIA) . We then investigated whether hypoxia, which regulated expression of PAR-2 in the mouse model of PH, could induce PAR-2 expression in PASMC. PAR-2 mRNA and protein levels were significantly increased after 24 hours exposure to 1% O 2 (Figure 2A through 2C), whereas no change in PAR-2 expression was detected when PASMC were exposed for 24 hours to 3% and 5% O 2 (Online Figure  VIB) . Accordingly, elevated hypoxia-inducible factor (HIF)-1␣ level was observed after 24 hours exposure to 1% O 2 but not after exposure to 5% O 2 (Online Figure VIC) . Analysis of the PAR-2 gene for the presence of putative hypoxia response elements (HRE) revealed 4 HRE flanking the PAR-2 coding sequence, located at positions Ϫ3996, Ϫ1630, ϩ1261, and ϩ1637. These HRE are of particular interest, because they indicate regulation of mRNA expression by HIF-1␣. Knockdown of HIF-1␣ by siRNA significantly decreased its mRNA level under normoxic and hypoxic conditions ( Figure 2D and 2E). PAR-2 expression remained unchanged in HIF-1␣-depleted cells exposed to normoxia but was diminished in HIF-1␣ knockdown cells on hypoxia exposure ( Figure 2D and 2E ). This suggests that HIF-1␣ controls hypoxia-mediated expression of PAR-2 in PASMC.
Figure 1. Protease-activated receptor (PAR)-2 expression is elevated in experimental and human pulmonary hypertension (PH). A,
Representative serial lung sections from mice exposed to normoxia or hypoxia stained for PAR-2 or ␣-SMA. Arrows indicate positive staining. B, Localization of PAR-2 and ␣-SMA in lung parenchyma of sham (control)-treated or MCT-treated rats, 28 days postadministration. Arrows indicate positive staining. C, Representative serial lung sections from donor and IPAH lungs stained for PAR-2 or ␣-SMA. Arrows indicate positive staining. MCT, monocrotaline; ␣-SMA, ␣-smooth muscle actin; IPAH, idiopathic pulmonary arterial hypertension.
Platelet-Derived Growth Factor-BB-Related Expression of PAR-2
We next investigated whether PDGF-BB, which is known to be involved in PH development, 21 can regulate PAR-2 expression in PASMC. Treatment of human PASMC with platelet-derived growth factor (PDGF)-BB increased PAR-2 expression in a time-dependent manner ( Figure 2F through 2H). Increased PAR-2 mRNA level correlated with elevated protein expression ( Figure 2F through 2H). The PDGF-BBinduced PAR-2 expression was diminished in the presence of a PDGF-BB neutralizing antibody or the PDGF receptor antagonist Imatinib ( Figure 2I and 2J). To evaluate the molecular mechanism of PDGF-BB-triggered PAR-2 expression, we applied pharmacological inhibitors of MAPK kinases and PI3K/Akt. Both MEK1/2 (PD98059) and PI3K/Akt (Wortmannin) inhibitors attenuated PAR-2 expression in response to PDGF-BB, whereas no effect of JNK (SP600125) and p38 (SB203580) inhibitors was seen (Online Figure VIIA and VIIB). Moreover, stimulation of PASMC with PDGF-BB increased ERK1/2 and Akt phosporylation but did not influence activation of JNK and p38 kinases (Online Figure VIIC) . Of note, PD98059 and Wortmannin did not affect phosphorylation of Akt and ERK1/2, respectively. This indicates that both inhibitors did not interfere with the activity of nontarget kinases. Because vascular endothelial cells were found to be the primary source of PDGF-BB both in hypoxia mouse model of PH and human IPAH lungs (Online Figure VIII) , we can speculate that PDGF-BB may act on PASMC in a paracrine fashion.
To decipher possible interplay between hypoxia-and PDGF-BB-driven PAR-2 expression, we first examined the effect of hypoxia on PDGF-BB production. Exposure of PASMC to hypoxia (1% O 2 ) stimulated PDGF-BB expression ( Figure 3A ). Depletion of HIF-1␣ did not abrogate hypoxia-induced PDGF-BB synthesis (Online Figure IXA) , indicating that hypoxia-triggered PDGF-BB production in PASMC is HIF-1␣ independent. Furthermore, there was no difference in HIF-1␣ mRNA and protein level between cells with and without PDGF-BB treatment under either normoxic or hypoxic conditions (Online Figure IXB and IXC). Hypoxiainduced PAR-2 expression was attenuated by PDGF-BB neutralizing antibody or the PDGF receptor antagonist Imatinib ( Figure 3B and 3C). To evaluate whether blockage of PDGF receptor and HIF-1␣ knockdown have additive inhibitory effect on hypoxia-driven PAR-2 expression, we pretreated PASMC with Imatinib or HIF-1␣ siRNA. PDGF Figure 3 . HIF-1␣ depletion and Imatinib impair hypoxia-driven PAR-2 expression. A, Expression of PDGF-BB in PASMC-exposed to hypoxia for 24, 48, and 72 hours. PBGD was used as a housekeeping control gene, nϭ4 to 6 per group. *PϽ0.05. B, Effect of hypoxia on PAR-2 expression in PASMC in the presence of Imatinib (2 mol/L) or neutralizing PDGF-BB antibody (10 g/mL) as assessed by Western blotting. C, Densitometric analysis of (B). Data are presented as percentage of control, nϭ3. *PϽ0.05. **PϽ0.01. D, Effect of HIF-1␣ knockdown and Imatinib treatment on PAR-2 expression in PASMC exposed to hypoxia. E, Densitometric analysis of (D), nϭ3. *PϽ0.05. **PϽ0.01. F, PAR-2 expression in lungs of hypoxia-exposed mice and hypoxia-exposed mice treated with Imatinib as indicated by Western blotting. G, Densitometric analysis of (F), nϭ5 per group. *PϽ0.05. H, Representative lung tissue sections from mice exposed to hypoxia and from mice exposed to hypoxia and treated with Imatinib stained for PAR-2 or ␣-SMA. I, PAR-2 expression in lung homogenates of rats treated with MCT or MCT and Imatinib as assessed by Western blotting. J, Densitometric analysis of (I), nϭ4 to 6 per group. *PϽ0.05. K, Representative lung tissue sections from MCT or MCT and Imatinib-treated rats stained for PAR-2 or ␣-SMA. HIF, hypoxia inducible factor; PAR, protease-activated receptor; PDGF, platelet-derived growth factor; PASMC, pulmonary artery smooth muscle cells; PBGD, porphobilinogen deaminase; MCT, monocrotaline.
receptor blockage and HIF-1␣ depletion alone diminished hypoxia-triggered PAR-2 expression; however, this effect was potentiated when Imatinib and siHIF-1␣ were applied simultaneously ( Figure 3D and 3E). This suggests that elevated PAR-2 level observed under hypoxic conditions is a cumulative result of 2 separate pathways (one HIF-1␣ dependent and another one HIF-1␣ independent but driven by PDGF) both activated by hypoxia.
Next, we examined PAR-2 expression in the lung tissue of mice exposed to hypoxia and rats treated with MCT after Imatinib application. As depicted in Figure 3F , 3G, 3I, and 3J, Imatinib administration attenuated PAR-2 synthesis in the lung tissue of hypoxia-exposed mice and MCT-injected rats. Most important, diminished PAR-2 expression was observed in SMC of pulmonary vessels of hypoxia-exposed mice ( Figure 3H ) and MCT-challenged rats ( Figure 3K ) after Imatinib treatment.
Hypoxia-Induced PH in PAR-2 ؊/؊ Mice
We next investigated the role of PAR-2 in vivo using the hypoxic mouse model of PH. After 21 days of hypoxia exposure, wild-type (WT) mice exhibited increased RVSP, but this increase was significantly attenuated in PAR-2 Ϫ/Ϫ mice ( Figure 4A ). The ratio of right ventricle to left ventricle plus septum weight (RV/(LVϩS)) increased from 0.36Ϯ0.03 (controls) to 0.56Ϯ0.04 (hypoxia) in WT mice, whereas in PAR-2 Ϫ/Ϫ mice no increase in RV/(LVϩS) was observed ( Figure 4B ). CO and TAPSE were significantly decreased in WT but not in PAR-2 Ϫ/Ϫ mice after hypoxia exposure ( Figure  4C and 4D). RVID was significantly elevated in hypoxiaexposed WT mice but virtually unchanged in hypoxiaexposed PAR-2 Ϫ/Ϫ animals in comparison with normoxia ( Figure 4E ). No significant change in SAP was observed in any of the experimental groups ( Figure 4F ). Next, the degree of muscularization was assessed in pulmonary arteries with a diameter between 20 and 70 m. In comparison with WT animals, PAR-2 Ϫ/Ϫ mice exhibited lower numbers of muscularized vessels (14.1Ϯ1.9 versus 7.5Ϯ0.9; Figure 4G ) following exposure to hypoxia. Representative pictures of small pulmonary vessels are depicted in Figure 4H . The number of proliferative cells in the vascular wall, as assessed by proliferating cell nuclear antigen (PCNA) staining, was attenuated in PAR-2 Ϫ/Ϫ animals exposed to hypoxia in comparison with WT mice ( Figure 4I ). Consequently, we explored the functional importance of PAR-2 in proliferation and migration of PASMC. PAR-2 silencing significantly reduced proliferation ( Figure 4J ) and migration ( Figure 4K 
PAR-2-Mediated Proliferative Effects of Tryptase
Because tryptase is known to activate PAR-2, we investigated the cellular effects of tryptase on PASMC. Stimulation of PASMC with tryptase led to phosphorylation of ERK1/2 kinase in a dose-dependent manner (Online Figure XIA and XIB). Activation of ERK1/2 was attenuated in the presence of the protease inhibitor leupeptin, indicating that the tryptase catalytic activity is required for the induction of ERK1/2 phosphorylation. Application of the PAR-2 agonist peptide (AP) and reverse peptide (RP) served as positive and negative control, respectively (Online Figure XIC and XID). Pretreatment of PASMC with siPAR-2 attenuated the tryptase-induced ERK1/2 phosphorylation ( Figure 5A and 5B). Moreover, incubation of PASMC with tryptase resulted in a time-dependent increase in expression of MMP-2 and the extracellular matrix protein fibronectin (FN; Figure 5C and 5D), which was strongly diminished by PAR-2 depletion ( Figure 5E 
Mast Cells and Tryptase Expression in Experimental and Human PH
Because mast cells are a potent source of the serine protease tryptase, we examined the number of mast cells in lung tissue in experimental and clinical PH. Significantly higher numbers of mast cells were observed within the lung parenchyma of hypoxic mice, MCT-injected rats, and IPAH patients. Of note, mast cells were localized in close proximity to pulmonary arteries and the bronchial tree ( Figure 6A through 6C). Correspondingly, tryptase (mouse mast cell proteinase-6) was elevated in hypoxia-induced PH ( Figure 7A and 7B), MCTinduced PH ( Figure 7C and 7D), and most important in samples from human lungs with IPAH ( Figure 7E and 7F). Immunohistochemical analysis of donor and IPAH lung sections showed increased numbers of tryptase positive cells in the lung parenchyma of IPAH patients ( Figure 7G and 7H). Moreover, double immunofluorescence staining of IPAH lung sections demonstrated presence of tryptase-positive mast cells within tunica media of remodeled pulmonary vessels ( Figure 7I ). In IPAH plasma samples, tryptase levels were elevated in comparison with those in healthy controls (5.1 pg/mL Ϯ0.35, nϭ21, and 2.9 pg/mL Ϯ0.21, nϭ20, respectively; Figure 7J ).
Effect of PAR-2 Antagonist on Hypoxia-Exposed Mice
To elucidate whether PAR-2 inhibition reverses PH, we treated mice exposed to hypoxia with the selective PAR-2 antagonist FSLLRY-NH 2 . PAR-2 antagonist application started 3 weeks after mice were exposed to hypoxia, thus at a time point when PH was already well established. Administration of the PAR-2 antagonist significantly lowered the hypoxia-induced increase in RVSP in comparison with the placebo group ( Figure 8A ). Right ventricular hypertrophy was not significantly changed in hypoxia-exposed mice treated with the PAR-2 antagonist ( Figure  8B ). However, PAR-2 antagonist caused a significant increase of CO and TAPSE in comparison with placebo ( Figure 8C and 8D). Furthermore, RVID was virtually normalized in the mice that received PAR-2 antagonist in comparison with placebotreated animals ( Figure 8E ). SAP was not affected in any experimental group ( Figure 8F ). In order to investigate the effect of PAR-2 antagonist on pulmonary vascular remodeling, the degree of muscularization of pulmonary arteries was analyzed. PAR-2 antagonist treatment significantly reduced the number of fully muscularized vessels in comparison with placebo control ( Figure 8G and 8H). Analysis of FN and MMP-2 expression in lung homogenates revealed strong increase of these proteins in , and systemic arterial pressure (SAP) (F) of WT and PAR-2 Ϫ/Ϫ mice exposed to normoxia and WT and PAR-2 Ϫ/Ϫ littermates exposed for 21 days to chronic normobaric hypoxia (10% O 2 ), nϭ5 to 9 per group. *PϽ0.05. **PϽ0.01. ***PϽ0.001. G, Degree of muscularization in small pulmonary vessels. The proportion of fully muscularized (M), partially muscularized (P), and nonmuscularized (N) vessels is given in percentage of total vessel count, nϭ6 per group. *PϽ0.05. ***PϽ0.001. H, Representative pictures of small pulmonary vessels of WT and PAR-2 Ϫ/Ϫ mice exposed to normoxia or hypoxia stained for von Willebrand factor and ␣-SMA. I, Representative lung sections of WT and PAR-2 Ϫ/Ϫ mice exposed to normoxia or hypoxia stained with PCNA. J, Impact of PAR-2 knockdown on PASMC proliferation as assessed by [ 3 H]thymidine incorporation, nϭ4. **PϽ0.01. K, Effect of PAR-2 knockdown on PASMC migration as assessed by cell counting of migrated cells. Representative filters with migrated cells are shown, nϭ6. *PϽ0.05. PAR, protease-activated receptor; PH, pulmonary hypertension; siUNC, universal negative control siRNA; n.s., not significant; PASMC, pulmonary artery smooth muscle cells; WT, wild-type; ␣-SMA, ␣-smooth muscle actin; PCNA, proliferating cell nuclear antigen.
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hypoxia-exposed placebo-treated mice in comparison with animals exposed to normoxia. This increase was significantly diminished by PAR-2 antagonist treatment ( Figure 8I and 8J).
Discussion
Protease-activated receptors (PARs) have been reported to play an important role in inflammation, tissue remodeling, fibroproliferation, and vascular homeostasis. 15, 16, 22, 23 In contrast to normal arteries exhibiting limited expression of PAR-2, the expression of PAR-2 is strongly elevated in the SMC of vascular lesions. 20, 24 In SMC, PAR-2 may mediate the contraction, cell migration, proliferation, hypertrophy, and production of extracellular matrix proteins. Because all these processes may contribute to vascular remodeling associated with the development of PH, we have investigated the potential role of PAR-2 in the pathogenesis of this disease.
In our study, we demonstrated elevated PAR-2 expression in the lungs of IPAH patients, mice exposed to hypoxia, and rats treated with monocrotaline. In contrast, we did not observe a consistent differential regulation of other PAR family members. Immunohistochemical analysis of lung sections revealed that PAR-2 was particularly expressed in PASMC with more intense staining in the diseased organ. A number of mechanisms-including mechanical stress, hypoxia, and secretion of cytokines and growth factors-could be responsible for elevated expression of PAR-2 observed in the medial compartment of pulmonary arterial wall. In line with this contention, exposure of PASMC to hypoxia or PDGF-BB, one of the growth factors involved in the pathogenesis of PH, induced PAR-2 synthesis. Moreover, hypoxiamediated expression of PAR-2 in PASMC was abrogated by HIF-1␣ depletion, PDGF-BB inhibitory antibody, or the PDGF receptor antagonist, Imatinib. However, PDGF-BB and HIF-1␣ did not show a mutual impact on their expression levels, and Imatinib and HIF-1␣ siRNA produced an additive inhibitory effect on PAR-2 expression under hypoxic conditions. This suggests that the hypoxic regulation of PAR-2 is the result of 2 separate pathways, where one is HIF-1␣dependent and the other HIF-1␣-independent but driven by PDGF-BB. The same inhibitory effect of Imatinib on PAR-2 expression was observed in the SMC layer of pulmonary vessels in both animal models of PH. Imatinib has previously been reported to reverse advanced pulmonary vascular disease in animal models of pulmonary hypertension and in patients suffering from IPAH. 21, 25 Thus, our findings may provide a link between elevated PDGF-BB levels in PH and increased PAR-2 expression in PASMC. However, it is possible that in addition to the PDGF-BB-and HIF-1␣dependent pathways, other factors known to be involved in PH, such as inflammatory signals, may also contribute to the induction of PAR-2 expression.
The importance of PAR-2 in the development of PH was underscored by our in vivo studies, in which PAR-2 Ϫ/Ϫ mice were protected against hypoxia-induced PH. More important, the developments in PAR-specific antagonists 26, 27 enabled us to apply the PAR-2 inhibitor, FSLLRY-amide, which reversed already established PH in the hypoxic mouse model. Both PAR-2 Ϫ/Ϫ and FSLLRY-amide-treated wild-type mice exhibited decreased RVSP, normalization of cardiac perfor-mance, and diminished muscularization of the small pulmonary arteries. In parallel to normalization of vessel morphology, the number of PCNA-positive cells in pulmonary arterial vessel walls was considerably reduced in PAR-2 Ϫ/Ϫ mice. These results were confirmed by our in vitro studies demonstrating that PAR-2 knockdown reduced proliferation and migration of PASMC in response to serum. Thus, it is tempting to speculate that PAR-2 regulates PASMC activities contributing to structural and functional changes of pulmonary blood vessels. This leads to increased pulmonary vascular resistance and then to increase in RVSP as well as right ventricular hypertrophy and dysfunction. Because no changes in cardiac PAR-2 expression were observed in wild-type mice exposed to hypoxia versus normoxia, the improved RVSP and right ventricular function observed in PAR-2 Ϫ/Ϫ mice and in mice treated with the PAR-2 antagonist most likely arises as a consequence of decreased right ventricular afterload (pulmonary vascular resistance) and not due to differential PAR-2 signaling in the heart. Importantly, hypoxia specifically up-regulated PAR-2 expression in the pulmonary vasculature; no change was noted in the systemic vessels under these conditions. Pulmonary specificity is also indicated by the absence of changes in systemic arterial pressure during hypoxia exposure of both PAR-2 Ϫ/Ϫ and wild-type mice treated with the PAR-2 inhibitor FSLLRY-amide. Together, these findings clearly indicate that PAR-2 represents a novel and promising therapeutic target for the treatment of PH.
A role for PAR-2 in regulating remodeling processes in the pulmonary vasculature has also been recognized by a very recent study utilizing PAR-2 overexpressing mice. PAR-2 overexpression induced pulmonary vascular remodeling and right heart hypertrophy in mice exposed to cigarette smoke, suggesting that PAR-2 may contribute to the development of pulmonary hypertension in smokers. 28 The interaction between inflammatory and structural cells in the development and progression of PH is becoming increasingly apparent. 29 In accordance with previously published reports, 30 -34 we detected increased number of mast cells in the lungs of IPAH patients, mice exposed to hypoxia, and monocrotaline-treated rats. Mast cells were typically located in close proximity to hypertrophic vessels within the lung parenchyma. Several studies have shown the importance of mast cell degranulation in experimental rat PH. 31, [33] [34] [35] For example, Bartelds et al. recently described attenuated pulmonary vascular remodeling following treatment with the mast cell stabilizer cromolyn in rats with flow-associated PH. 35 We have significantly expanded on these previous findings by demonstrating for the first time the importance of the tryptase-PAR-2 axis in the pathogenesis of PH, thus providing potential mechanistic explanations for the previously identified critical role of mast cells in PH. Our data clearly demonstrate a key role of PAR-2 as a target receptor for mast cell tryptase during the development of PH. Accordingly, elevated levels of tryptase were measured in lung tissue in experimental and human PH and in plasma from IPAH patients. Moreover, our findings indicate that PAR-2 and the tryptase-PAR-2 axis most likely contribute to the vascular remodeling process in PH by more than one mechanism. Indeed, our in vitro studies demonstrated that proliferation/ migration of PASMC as well as production of fibronectin and MMP-2 by this cell type in response to tryptase challenge are mediated by PAR-2, and that all these processes can effec-tively be blocked by PAR-2 silencing. This is in line with previously published reports documenting the proproliferative effects of tryptase toward different cell types including lung fibroblasts, 36 endothelial cells, tracheal SMC, 37 and bronchial epithelial cells, 11 and showing the ability of tryptase , and systemic arterial pressure (SAP) (F) in normoxic controls and animals exposed to hypoxia treated with placebo or PAR-2 antagonist; nϭ8 to 10 per group. *PϽ0.05. ***PϽ0.001. G, Degree of muscularization in small pulmonary vessels. The proportion of fully muscularized (M), partially muscularized (P), and nonmuscularized vessels (N) is given in percentage of total vessel count; nϭ5 per group. *PϽ0.05. ***PϽ0.001. H, Representative pictures of small pulmonary vessels of normoxic mice and animals exposed to hypoxia treated with placebo or PAR-2 antagonist stained for von Willebrand factor and ␣-SMA. I, FN and MMP-2 expression in lung samples from mice exposed to normoxia and littermates exposed to hypoxia challenged with placebo or PAR-2 antagonist. J, Densitometric analysis of (I), nϭ5 to 8 per group. **PϽ0.01. ***PϽ0.001 versus normoxia. #PϽ0.05. ##PϽ0.01versus placebo hypoxia. PAR, protease-activated receptor; PH, pulmonary hypertension; ␣-SMA, ␣-smooth muscle actin; FN, fibronectin.
to induce synthesis of extracellular matrix proteins in rat pancreatic stellate cells and MMP-9 release from airway epithelial cells. 22 We also demonstrated that PAR-2 mediates tryptase-induced PASMC proliferation and production of fibronectin and MMP-2 through activation of the ERK1/2 signaling cascade, which is an important mitogenic signaling pathway implicated in many cellular processes. The central role of ERK1/2 in PAR-2-dependent signaling events has previously been demonstrated in the breast cancer cell line MDA-MB-231 38 and in HaCaT keratinocytes, 39 leading to increased production of vascular endothelial growth factor and enhanced secretion of transforming growth factor-␤1, respectively. Taken together, our in vitro studies have identified the PAR-2-ERK1/2 signaling pathway as a common pathway mediating different tryptase-induced cellular effects relevant for the pathogenesis of PH. In our animal studies we confirmed that all these mechanisms indeed seem to be important and relevant also in the in vivo situation: we found increased muscularization of the small pulmonary arteries, enhanced proliferation of PASMC, and increased expression of fibronectin and MMP-2 in lung tissue in hypoxia-induced PH, and all these processes were significantly reduced in PAR-2 Ϫ/Ϫ mice and in response to treatment with the PAR-2 antagonist, respectively. Together, our findings suggest that PAR-2/PAR-2-dependent signaling triggers pulmonary vascular remodeling in PH by more than one mechanismincluding regulation of muscularization, deposition of structural matrix proteins, and extracellular matrix turnover-and that targeting this pathway can affect different pathogenetically relevant mechanisms in PH. These observations make PAR-2 an attractive and-as demonstrated in the animal studies-effective target for therapeutic interventions in PH.
At this point, we cannot exclude that PAR-2 could contribute to the pathogenesis of PH by additional mechanisms, thereby influencing other PASMC functions or by impacting the activities of other cell populations. For example, PAR-2 is also expressed by endothelial cells and can regulate inflammation, 40 intracellular calcium mobilization, 41 and activation of growth factor-dependent pathways, 42 processes that take place during PH development. Similarly, in addition to tryptase, other known activators of PAR-2, such as trypsin or components of the coagulation system, could likewise contribute to the activation of this receptor in vivo and thus to the development of vascular remodeling and PH. In this context, factor Xa was previously found to induce mitogenesis of coronary SMC via PAR-2. 43 Moreover, Delbeck et al recently reported that selective inhibition of factor Xa prevents RV dysfunction and hypertrophy in monocrotaline-injected rats; however, the potential role of PAR-2 was not assessed. 44 Future studies are required to investigate whether further mechanisms exist by which PAR-2 contributes to the development of PH and whether activators other than tryptase are crucially involved.
Collectively, our results indicate that hypoxia together with PDGF-BB stimulates PAR-2 synthesis in PASMC. Activation of PAR-2 triggers pulmonary vascular remodeling by regulating PASMC proliferation and migration, deposition of structural matrix proteins, and extracellular matrix turnover, thereby leading to the development of PH. Targeting PAR-2 offers a novel therapeutic potential for the treatment of vascular remodeling in PH.
Novelty and Significance
What Is Known?
• Pulmonary hypertension (PH) is a fatal disease characterized by smooth muscle hypertrophy and vascular wall remodeling. • Accumulating evidence suggests that inflammatory cells such as mast cells may play an active role in the development of PH. • Tryptase, mast cell mediator, may induce proliferation of various cell types via the protease-activated receptor (PAR)-2.
What New Information Does This Article Contribute?
• PAR-2 levels are increased in the lungs of patients with idiopathic pulmonary arterial hypertension (IPAH) and animal models of PH. 
Supplemental Methods
Mast cell staining Mast cells were routinely stained with 0.5% toluidine blue. The number of mast cells in the lung parenchyma was determined by viewing the tissue at 20x by light microscopy and counting the number of positive cells in 10 non-overlapping fields. Areas around large blood vessels and bronchi and near pleural surfaces were avoided.
Tryptase immunoassay
A Maxisorp microtiter plate (Nunc, Wiesbaden, Germany) was coated overnight at 4°C with 10μg/ml mouse anti-tryptase antibody (Chemicon, Temecula, CA) in 50 mmol/L NaHCO 3 , pH 9.5. The plate was blocked for 1h at room temperature with 3% (wt/vol) BSA in PBS containing 0.1% (v/v) Tween-20 (PBS-T) and then incubated with the cell-free plasma. The plasma samples were prediluted 1:10 and 1:20 with PBS-T. After 1h incubation at 37°C, the plate was extensively washed with PBS-T and then incubated for 2h at room temperature with rabbit anti-tryptase antibody (Calbiochem, Darmstadt, Germany), followed by peroxidase-linked secondary antibody (Dako, Gostrup, Denmark 
Hypoxia response element (HRE)
Human PAR-2 (F2RL1; NT_006713.15) promoter obtained from (http://www.ncbi.nlm.nih.gov/mapview/) was screened for presence of hypoxia response elements (HRE). The consensus sequence chosen for HRE was "ACGTGS", were S can be -G or C. The promoter region was screened 5,000bp downstream and upstream from the coding sequence for the occurrence of this consensus sequence.
Cell culture and transfection
PASMC used for all the experiments applied in the manuscript were isolated from nonutilized human donor lungs harvested for lung transplantation that were not implanted due to lack of compatibility (for instance, oversized grafts). PASMC were isolated from human resistance pulmonary arteries (from third intrapulmonary branch, diameter<1mm). The purity of PASMC was confirmed using immunofluorescence staining for smooth muscle-specific isoforms of α-actin and myosin (minimum 95% of cells stained positive) and lack of staining for von Willebrand factor. All experiments were performed with cells in passage 3-6 and growth arrested by serum deprivation for 24h. To investigate the effect of hypoxia on PAR-2 and PDGF-BB expression, cells were either exposed to 1%, 3% or 5% O 2 (hypoxia) or to 21% O 2 (normoxia) for indicated time-points. Hypoxia experiments were performed in hypoxia chamber for cell culture under controlled conditions (BioSpherix) in commercially available buffered medium (VascuLife SMC Medium Complete Kit) to ensure stable pH and PCO 2 levels under hypoxic versus normoxic conditions. In this respect, after 24 hours of culture the pCO 2 was 28mmHg and pH 7.29 in hypoxic condition (1%O 2 ) as compared to 28mmHg and pH 7.24 under normoxia. Pre-designed, commercially available siRNA sequences directed against human PAR-2 and HIF-1α were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Ambion (Darmstadt, Germany), respectively. To control for non-specific gene inhibition of the siRNAs used in this study, a universal negative-control siRNA sequence was employed (Ambion). Cells were transfected with siRNA (100nmol/L) using the X-treme Gene siRNA Transfection Reagent (Roche, Mannheim, Germany) or Effectene Transfection Reagent (Qiagen, Hilden, Germany). The siRNA-mediated downregulation of the target gene was assessed 48h after transfection by RT-PCR and western blotting. PASMC were treated with 7nmol/L tryptase (Calbiochem, San Diego, CA) or 10 -4 mol/L of either PAR-2-actvating peptide (2-furoyl-LIGRLO-NH 2 ) or reverse peptide (transcinnamoyl-OLIGRL-NH 2 ) as a control. Stimulation time was 15min for the analysis of ERK1/2 phosphorylation. PDGF-BB (R&D Systems, Wiesbaden, Germany) was used at concentration 10ng/ml for indicated time-points. In some experiments 1h before hypoxia exposure, cells were treated with 2µmol/L STI571 (Imatinib/Gleevec®; generous gift from S. Pascoe and E. Buchdunger, Novartis, Novartis Horsham Research Centre, Horsham, United Kingdom), 10μg/ml blocking PDGF-BB antibody (R&D Systems), or 10μg/ml respective IgG control. In other experiments, PASMC were treated with 30μmol/L PD98059, 8μmol/L SP600125, 80nmol/L Wortmannin or 5μmol/L SB203580 inhibitors (all from Calbiochem, Darmstadt, Germany) 1h prior to the addition of PDGF-BB and PAR-2 expression was evaluated at 48h treatment.
RNA isolation and real-time PCR
RNA was isolated using the RNeasy Miniprep Kit (Qiagen, Hilden, Germany) according to the manufacture's protocols. Quality and quantity of RNA was determined by 1.5% (m/v) agarose gel and UV absorbance (Nanodrop, Rockland, IL). For cDNA synthesis, reagents and incubation steps were applied as described previously 1 . Real-time PCR was used for relative quantification of PAR-2 using PBGD (HMBS) as the reference gene 2 . Primer sequences were as follows: human PBGD (FP: 5'-CCC ACG CGA ATC ACT CTC AT-3'; RP: 5'-TGT CTG GTA ACG GCA ATG CG-3'), human PAR-1 (FP: 5'-CCG CCT GCT TCA GTC TGT G-3' RP: 5'-GGT TCC TGA GAA GAA ATG ACC G-3'); human PAR-2 (F2RL1; NM_005242; FP: 5'-CTT CCA GGA GGA TGC GGA G-3', RP: 5'-TGG GAT GTG CCA TCA ACC TTA-3'); human PAR-3 (FP: 5'-GCA GCT GCT GGC CTC CT-3'; RP: 5'-GCT CCA CGA AAG GTC TTA ATG G-3'); human PAR-4 (FP: 5'-CCC AGC GTC TAC GAC GAG AG-3' RP: 5'-GCA CAG ACT TGG CCT GGG TA-3'); human PDGF-BB (FP: 5'-AGG AGC CTG GGT TCC CTG ACC-3'; RP: 5'-CTG CAC CTC CAC ACA GGG CG-3'), human HIF-1alpha (FP: 5'-CAA GAA  GCC CTA ACG TGT TAT CTG-3'; RP: 5'-CGC TTT CTC TGA GCA TTC TGC-3'); murine  PBGD (FP: 5'-GGT ACA AGG CTT TCA GCA TCG C-3'; RP: 5'-ATG TCC GGT AAC GGC  GGC-3'), murine PAR-1 (FP: 5'-TGA TCG TCG CCC TCG G-3'; RP: 5'-GGT TCA CCG  TAG CAT CTG TCC-3'), murine PAR-2 (F2RL1; NM_007974; FP: 5'-GGA CCG AGA ACC  TTG CAC C-3'; RP: 5'-CTA CCG GAA CCC CTT TCC C-3'), murine PAR-3 (FP: 5'-AAA  TCC TTA TCT TGG TTG CAG -3'; RP: 5'-GGC TTT GCT GAG TTG TCT GAA -3') , murine PAR-4 (FP: 5'-ACC CCC AGC ATC TAC GAT GA-3'; RP: 5'-GAG GAC TTC GGC TCC TTG AGT-3'). The reactions were performed in an ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA).
Protein isolation and western blotting
Protein extracts were separated on a SDS polyacrylamide gel, followed by electrotransfer to a PVDF membrane. After being blocked with 5% non-fat dry milk in TBS-T buffer, the membrane was incubated overnight at 4°°C with one of the following antibodies: anti-PAR-2 (kindly provided by W. Ruf), anti-PAR-1 (Biomol, Hamburg, Germany), anti-PAR-3, anti-PAR-4 (both from Santa Cruz Biotechnology), anti-Tryptase, anti-mast cell proteinase-6, anti-MMP-2 (all from R&D Systems), anti-fibronectin (Abcam, Cambridge, MA), anti-phospho ERK1/2, anti-ERK1/2 (both from Cell Signaling), anti-HIF-1α (BD Bioscience), or anti-ß-actin (Sigma-Aldrich). After 1h of incubation with peroxidase-labelled secondary antibody (Dako, Gostrup, Denmark) proteins were detected by using ECL Plus Kit (Amersham Biosciences, Freiburg, Germany).
Immunofluorescence
For immunofluorescence analysis, PASMC grown on glass slides were fixed for five minutes in cold methanol and rinsed five times in PBS. Afterwards, the cells were blocked for 2h with 3% BSA in PBS, and then incubated overnight at 4°C with anti-PAR-2 (1:100; (kindly provided by W. Ruf) and anti-α-sma antibodies (1:400; Sigma-Aldrich). Finally, the slides were washed three times with PBS, incubated with anti-rabbit Alexa-555 and anti-mouse Alexa-488 (Invitrogen, Karlsruhe, Germany) and mounted with fluorescence Vectashield mounting medium (Vector, Burlingame, CA). Cell nuclei were counterstained with 4',6diamidino-2-phenyindole dihydrochloride (DAPI, Sigma-Aldrich). For microscopic inspection, a Leica DMR microscope was used.
Rat PASMC isolation
Rat microvascular PASMC were isolated from precapillary pulmonary vessels as described previously for mice PASMC 3 .
Proliferation assay
Cell proliferation of PASMC was assessed by [ 3 H]-thymidine incorporation. For this analysis, cells were seeded at a density of 15×10 4 /ml on 48-well plates. Cells (70% confluent) were serum-starved for 24h and then treated with 7nmol/L Tryptase for 24h. In some experiments cells were transfected with scrambled siRNA or siRNA targeted against PAR-2 48h prior Tryptase application. During the last 4h, cells were pulsed with 0.6µCi of [ 3 H]-thymidine (GE Healthcare, Little Chalfont, UK). Plates were washed three times with ice-cold PBS and the cells were solubilized in 0.5mol/L NaOH. The cellular [ 3 H]-thymidine content of each well was quantified by scintillation counting.
Migration
The ability of human primary PASMC to migrate to the chemotactic stimulus of 5% FCS, in the presence of PAR-2-specific siRNA or scrambled siRNA was assessed using Transwell inserts with 8.0µm pores (BD, Heidelberg, Germany). To quantify the migrated cells, inserts were removed after 18h, the inner surface scraped, and the outer surface was fixed and stained using the crystal violet solution (Sigma, Munich, Germany). The total number of migrated cells on the entire filter was counted.
Animal experiments
All animal experiments were performed in accordance with institutional and national guidelines for the care and use of experimental animals. Adult male C57Bl/6J mice (20-24g) were obtained from Charles River WIGA GmbH (Sulzfeld, Germany). Animals were housed under controlled temperature and lighting, and were allowed food and water ad libitum. For hypoxic exposures, wild-type and PAR-2-/-mice were placed in a ventilated chamber system with a FiO 2 of 0.10. After indicated time points, mice were sacrificed by intraperitoneal injection of sodium pentobarbital, and lungs were extracted. The lungs were either immediately snap-frozen in liquid nitrogen or harvested and processed for histological embedding and sectioning. Pulmonary hypertension was induced in adult male Sprague-Dawley rats by monocrotaline injection as described previously 4 . After 21 days, rats challenged with monocrotaline and mice exposed to hypoxia were randomized and treated once daily with STI571 (Imatinib/Glivec®, Norvatis) at the dose of 100 mg/kgbw. The treatment was done orally by gavage for 14 days. The control animals received vehicle (methylcellulose). The therapeutic effects of PAR-2 inhibition were assessed in mice exposed to hypoxia for 35 days. Briefly, 20 animals were kept in hypoxic conditions to develop pulmonary hypertension. After 21 days, animals were randomized to receive daily intraperitoneal injections of either PAR-2 antagonist FSLLRY-amide (4 mg/kgbw, Bachem, Bubendorf, Switzerland) or placebo.
Assessment of right heart hypertrophy and vascular remodeling
After the right ventricular pressure was recorded, the animals were exsanguinated and the lungs and heart were isolated. The right ventricle (RV) was dissected from the left ventricle plus septum (LV+S) and these samples were weighed to obtain the right to left ventricle plus septum ratio (RV/(LV+S)). The lungs were perfused with a solution of 10% phosphate buffered formalin (pH 7.4). At the same time 10% phosphate buffered formalin (pH 7.4) was administered into the lungs via the tracheal tube at a pressure of 20cm H 2 O. These specimens were processed for light microscopy by routine paraffin embedding. The degree of muscularization of small peripheral pulmonary arteries was assessed by double-staining the 3μm sections with an anti-α-smooth muscle actin antibody (α-SMA; dilution 1:900, Sigma, Saint Louis, Missouri) and anti-von Willebrand factor antibody (vWF; dilution 1:900, Dako, Hamburg, Germany) modified from a protocol described elsewhere 5 . Dewaxed and rehydrated sections were subjected to proteolytic antigen retrieval with 0.1% trypsin in 0.1% calcium chloride (pH 7.6) at 37°C for 8min and stained with the avidin-biotinperoxidase complex method with 3, 3-diaminobenzidine as a substrate (ABC Elite, Vector Laboratories, Burlingame, USA). Sections were counterstained with hematoxylin and examined by light microscopy using a computerized morphometric system (Qwin, Leica, Wetzlar, Germany). At 40x magnification, 50-60 intraacinar vessels (20-70µm in diameter) accompanying either alveolar ducts or alveoli were analyzed by an observer blinded to treatment in each mouse. As described, each vessel was categorized as nonmuscularized, partially muscularized or fully muscularized 5 . The percentage of pulmonary vessels in each category was determined by dividing the number of vessels in that category by the total number counted in the same experimental group.
Cardiac and hemodynamic parameters.
Anesthesia was induced with isoflurane gas and maintained with 1.0 -1.5% isoflurane in room air supplemented with 100% O 2 . Mice were laid supine position on a heating platform with all legs taped to ECG electrodes for heart rate (HR) monitoring. Body temperature was monitored via a rectal thermometer (Indus Instruments, Houston, TX). The chest of the mice was shaved and treated with a chemical hair remover to reduce ultrasound attenuation. To provide a coupling medium for the transducer, a pre-warmed ultrasound gel was spread over the chest wall. Transthoracic echocardiography was performed with Vevo770 high-resolution imaging system equipped by 30-MHz transducer (VisualSonics, Toronto, Canada). RV internal diameter (RVID) was measured as the maximal distance from the RV free wall to the septum from the apical four chamber view. For determine tricuspid annular plane systolic excursion (TAPSE) M-mode cursor was oriented to the junction of the tricuspid valve plane with the RV free wall using the apical four chamber view. Cardiac output (CO) was calculated as the product of the velocity-time integral of the pulsed-Doppler tracing in the LV outflow tract, the cross-sectional area of the LV outflow tract, and the HR. All echocardiographic studies were performed by an experienced sonographer who was blinded to experimental groups, results of invasive and morphometric studies and calculated off-line using tool section of the Visual Sonics Vevo770 system. Right ventricular systolic pressure (RVSP) was measured as described previously 5 . 
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